Date: 2015-11-09
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Company: OncoMed Pharmaceuticals (USA - CA)
Product: vantictumab (anti-Fzd7, OMP-18R5)
Action
mechanism: monoclonal antibody/Wnt pathways inhibitor. OMP-18R5 is a monoclonal antibody that binds selected receptors in the Wnt signaling pathway and is the first antibody to specifically block these targets to enter human studies. Vantictumab is part of OncoMed's collaboration with Bayer. Bayer can elect to exercise its options on vantictumab through completion of Phase 1b trials.
Disease: non-small cell lung cancer (NSCLC)
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On November 9, 2015, OncoMed Pharmaceuticals presented preclinical data novel biomarker discoveries related to vantictumab (anti-Fzd7, OMP-18R5) in non-small cell lung cancer (NSCLC) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. In a preclinical patient-derived xenograft non-small cell lung cancer (NSCLC) model, OncoMed researchers confirmed the anti-tumor activity of vantictumab both as a single-agent and in combination with taxane treatment. Sequential dosing (the administration of vantictumab two days prior to treatment with paclitaxel) was more efficacious than same-day dosing. Pharmacodynamic biomarkers showed that vantictumab inhibits genes in cancer stem cell pathways that support its mechanism of action. Importantly, LEF1, a key transcription factor in the Wnt pathway was identified as a potential predictive biomarker for treatment response in patient-derived xenograft models. LEF1 is being retrospectively evaluated as a predictive biomarker in OncoMed's ongoing Phase 1b clinical trial of vantictumab in combination with docetaxel in patients with previously treated NSCLC.
